Subscriber access provided by University at Buffalo Libraries
Communication
General and Practical KOMe/Disilane-Mediated Dehalogenative Deuteration of (Hetero)Arylhalides Xin Wang, Ming-Hui Zhu, David P Schuman, Dayou Zhong, WenYan Wang, Lin-Yang Wu, Wei Liu, Brian M. Stoltz, and Wen-Bo Liu J. Am. Chem. Soc., Just Accepted Manuscript • DOI: 10.1021/jacs.8b07597 • Publication Date (Web): 03 Aug 2018 Downloaded from http://pubs.acs.org on August 3, 2018
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Journal of the American Chemical Society
General and Practical KOMe/Disilane-Mediated Dehalogenative Deuteration of (Hetero)Arylhalides Xin Wang,† Ming-Hui Zhu,† David P. Schuman,# Dayou Zhong,† Wen-Yan Wang,† Lin-Yang Wu,† Wei Liu,† Brian M. Stoltz,# Wen-Bo Liu*† †
Engineering Research Center of Organosilicon Compounds & Materials, Ministry of Education, College of Chemistry and Molecular Sciences, Wuhan University, 299 Bayi Rd, Wuhan, Hubei, China, 430072 #
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 91125, United States
Supporting Information Placeholder A B S T R A C T : Herein we describe a general, mild and
scalable method for deuterium incorporation by potassium methoxide/hexamethyldisilane-mediated dehalogenation of arylhalides. With CD3CN as a deuterium source, a wide array of heteroarenes prevalent in pharmaceuticals and bearing diverse functional groups, are labeled with excellent deuterium incorporation (>60 examples). The ipsoselectivity of this method provides precise access to libraries of deuterated indoles and quinolines. The synthetic utility of our method has been demonstrated by the incorporation of deuterium into complex natural and drug-like compounds.
Deuteration has found widespread applications in chemistry and related fields, such as organic synthesis,1 mechanistic studies,2 quantitative analyses,3 and pharmaceutical discoveries and developments.4 Deuterium labeling techniques are broadly utilized as efficient tools for optimization of metabolic stability and toxicity of drugs.5 Moreover, introducing deuterium into active pharmaceutical ingredients may enhance their pharmacokinetic and pharmacodynamics properties.6 Therefore, deuterium incorporation is clinically meaningful and has the potential to enable new drug discovery.4 Development of efficient methods for deuteration has recently attracted much attention.7,8 Dehalogenative deuteration of widely available arylhalides is a convenient way to access versatile deuterated products. A number of methods enabling such transformation have been reported and widely used,7–10 such as lithium-halogen exchange,9 transition-metal-catalyzed dehalogenative reduction,10a–f and organotin10g or sodium amalgam10h mediated halogen abstraction (Scheme 1a – c). However, the necessities of precious metal catalysts/ligands, toxic tin reagents, or highly reactive alkyllithium reagents under cryogenic conditions
disadvantage the applications of those protocols. Crucially, one of the major challenges and potential limitations in halogen/lithium exchange is the poor tolerance of functional groups.9 Alternatively, direct hydrogen isotope exchange (HIE) was found to be a straightforward strategy,11 and great advances were made recently by the Chirik11f and Macmillan11g groups using iron and iridium photoredox catalysis respectively. Although these are powerful methods, achieving precise site-selectivity and high deuterium incorporation is still challenging. Therefore, general and mild methods with broad substrate scope, precise selectivity, and excellent deuterium incorporation are highly desirable. Recently, we have developed a simple dehalogenative deuteration strategy using a combination of potassium methoxide (KOMe) and hexamethyldisilane (Me3SiSiMe3) in CD3CN at room temperature (Scheme 1d). This mild method works well with arylhalides and alkenylhalides, and tolerates a wide range of functionalities. Moreover, deuteration can be easily controlled as the ipso-deuteration products are formed in a site-specific manner. Herein we wish to report the preliminary studies of this methodology. 12 Scheme 1. Deuterium Incorporation w ith Ar ylhalides. a Transition-Metal-Catalyzed Dehalogenative Deuteration FG
Ar
FG
[Pd] or [Ni]
I/Br/Cl
R 2CDOH, CD 3OD, or Et 3SiD, etc
Ar
D
Ar
D
Ar
D
Ar
D
b Radical Mediated Dehalogenative Deuteration FG
Ar
nBu
Br/I
3SnH/D,
FG
THF-d8
or Na-Hg, MeOD
c Lithium-Halogen Exchange Strategy (Stepwise Procedure) FG
Ar
Br/I
1) RLi –78 ºC
FG
Ar
2) D
d KOMe/Disilane Mediated Strategy (In Situ Procedure) FG
Ar
Br/I
ACS Paragon Plus Environment
KOMe, Me 3SiSiMe3 CD 3CN, 25 ºC
FG
subsequent deuteration
in situ deuteration
FG
Journal of the American Chemical Society 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 2 of 5
Scheme 2. Substrate Scope Studiesa Ar
D
D
D
N Me
MOM
2b, 92%c
4g, 89%b D
D N
OBn
O 4n, 79%c
4o, 98%b
D
F
R
5e, R = (E)-CH 2CH=CHPh, 88%b 5f, R = CH 2CH 2CH=CH 2, 64%c
N
Me
Me
4b, 61%e D
CN
tBu
4r, 72%c,d
O
4s, 88%c
(35% O 5g, 62%b
D) f
D
N
O N
6a, 80%c
N
O
D 6b, 87%e
OR
D
N
N
5
[5b (R = H), 76% + 5b' (R = TMS), 18%] c
N
N
4m, 79%c
D
NMe 2
5a, 63%c
Et
Et
4l, 83%b
D
(100% D) f
N
S O O
O
O
tBu
4d, 85%b
(64% D) f
4k, 79%c,d
O
(81% D) f
D
D
D
4j, 60%b D
S
4c, 75%c,d
N
D O
tBu
BPin 4q, 82%b
4p, 75%b
4i, 82%b D
NMe 2
Cl
N
(100% D) f
D
D NMe 2
D
Me 4h, 80%c
D D
N
4a, 83%d,e
N
D Me
4f, 92%b
3b, 75%b,d D
OMe
D
4e, 85%e
D
3a, 91%c
D
OMe
10
D
Me
D
2d, 90%c
2c, 61%b
Me
S (32% D) f
N Bn N
D
D
D
N
N
Bn
2a, 87%b
D
D
N
Ar
CD 3CN, 25 °C D
D
N
KOMe (2 equiv), Me 3SiSiMe3 (2 equiv)
Br/I
O
D
R
R = Cl, 5c, R = N 3, 5d, 91%b D
OMOM OMOM
N 6c, 89%e
5
82%b
6d, 67%e
D
N Bn 6e, 80%c
a
Reactions were conducted on 0.5 mmol scale. bWith 20 equiv of CD3CN. cWith 50 equiv of CD3CN. dWith KOMe (4 equiv) and Me3SiSiMe3 (4 equiv). e0.2 mmol scale with 1 mL CD3CN. fProton/deuterium exchange ratio of acidic protons with CD3CN.
Our investigations started with 1-methyl-5-bromoindole (1a) as a model substrate. Extensive optimization experiments identified that treatment of 1a with KOMe, Me3SiSiMe3, and a relatively cheap deuterium source– CD3CN (20 equiv) led to the desired product 2a in excellent yield (see Table S1 in SI for condition optimizations and discussions). Iodoindole shows similar reactivity, but chloroindole or fluoroindole is completely inert. It is worth noting that the reaction occurs at room temperature with exclusively deuterium incorporation and without the formation of silylation byproducts.13 With the optimized conditions in hand, we next turned our efforts to investigate the scope of substrates (Scheme 2). 5Bromoindoles with various N-protecting groups such as Me, Bn, allyl, and MOM, all provided the corresponding deuterated products (2a – 2d) in 61 – 92% yield. Many other pharmaceutically important heterocyclic scaffolds, including quinoline (3a), isoquinoline (3b), pyridine (4a), (tetrahydro)carbazole (4b and 4c), benzothiophene (4d), and thiophene (4e), all provided the deuterated heterocycles in moderate to good yield (61 – 91 %). Naphthalenes and fluorene were also compatible delivering the corresponding products (4f, 4g and 4h) smoothly. Next, we explored the electronics effect of substituents on arylbromides. Diverse functionalities such as pyridine (4i), nitrile (4j), epoxide (4k), sulfone (4l), amine (4m), morpholine (4n), benzyloxy (4o), were all well tolerated and offered access to deuterium derivatives in 60 – 98% yield. Products 4p and 4q were obtained without affecting the chloride and fluoride. In particular, boronate (Bpin) containing product 4r was
successfully synthesized in 72% yield which allows the streamline derivatizations of this deuterated moiety. Surprisingly, the debromination proceeded efficiently even with a sterically-encumbered substrate (2,4,6-tri-tertbutylbenzyl bromide) to give product 4s in 88% yield. To further elaborate the functional group compatibility of this chemistry, a variety of oxygen-tethered benzyl bromides were prepared and subjected to the standard conditions (5a – 5g). To our delight, substrates with a side chain containing amide (5a), free alcohol (5b), chloride (5c), azide (5d), internal or terminal olefins (5e and 5f), and terminal alkyne (5g) all underwent debrominative deuteration smoothly resulting in the corresponding products in 62 – 94% yield. Interestingly, a free alcohol was partially protected in situ to form silyl ether as well (i.e., 5b, see SI).14 In addition, benzooxazole, pyrimidine, and piperiazine containing deuterated compounds (6a – c) were also successfully accessed in 80% – 89% yield. Finally, the reactions with methoxymethyl-protected (S)-3,3’-dibromo-BINOL and alkenylbromide furnished products 6d and 6e in 67% and 80% yield, respectively. Several additional points regarding the substrate scope investigations are noteworthy. Sensitive functionalities that are incompatible with alkyl lithium, such as epoxide, nitrile, quinoline, pyrimidine etc, are well tolerated. For instance, treatment of epoxide S4k and nitrile S4j under halogen/lithium exchange conditions resulted in cyclized 4k’ and 4j’ as the major products (eqs 1 and 2). A direct comparison with previously strategies demonstrated that
ACS Paragon Plus Environment
Page 3 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Journal of the American Chemical Society
Scheme 3. Deuterium Incorporation into Pharmaceutically important molecules and Scale- up Reactiona a
Deuterium Labeling of Drugs and Natural Product Derivatives O
Me
Me Me
Me
D N
O
Me 7b, 95% Me from Glucofuranose derivative
D
7a, 95% from L-Menthol derivative
D
D
D
Me
Me
N
Me O
b
H
MeO
Me
H (100% D) b
O
Me
3
Me
7m, 68% Deuterated Methyl Estrone
Me
3
5
(100% D) b
H
Me H
H H
D
Me O
2) deuteration
Me
3
Me
Me
7k, 74% 7l, 85% from Estrone derivatives
3
3
Scale-up Reaction D
KOMe Me 3SiSiMe3
Br
Me
H
MeO
H
MeO c
1) HBr, DMSO, EtOAc
N
CD3CN (20 equiv)
N
Me
Me
Me
7n, 72% Deuterated Methyltocopherol
Methyltocopherol
Me D
N
O
7j, 82% from Ethynyl Estradiol derivative
one-pot
O
D 7f, 91% Deuterated Diphenhydramine
7e, 79% Deuterated Methylduloxetine
D
Me
N
D N
MeO
Me 3
N
Me
H
One-pot Halogenation/Deuteration
MeO
H
MeO
H
2
Me Me 7h, 91% 7i, 83% Deuterated Clomipramine Deuterated Aplysamine-1
Me 7g, 79% Deuterated Imipramine
D
N
H
N
Me
O
Me
D
7d, 74% Deuterated Pheniramine
D
N
(54% D) b
HO Me
D Me
N
Me
3
Cl
D
Me
N
N Me
O
D
N
N
Me Me
7c, 73% Deuterated Naftifine Me
S
N
O O O
O
Me
D O
1a (1.05 g)
2a, 90% (0.59 g)
a
See SI for the detailed reaction conditions. bProton/deuterium exchange ratio of acidic protons with CD3CN.
our chemistry not only allows a broad substrate scope but also offers a positional complement to recently reported twostep procedure of phosphorium salt formation/deuteration of pyridines and diazines12a (see Scheme S1 in SI for the comparison results with halogen-lithium exchange, transition-metal catalysis, and sequential phosphoration/deuteration). Secondly, substrates bearing acidic protons (i.e., α-position of nitrile, amide, and sulfone) undergo proton/deuterium exchange with CD 3CN. Finally, with respect to known limitations, monosubsituted or 1,2disubstituted linear alkenylbromides gave eliminated alkynes without formation of the desired deuterated products. O
O Br
Br Br
CN
Scheme 4. Combinatorial Synthesis of Libraries of Deuterated Indoles (a) and Quinolines (b)a a
D
1) tBuLi, THF, –78 $C
4k', 72% yield D
CN
4j, 5% yield
N
Me
D
D
N 3d, 84%c
3c, 31%c
N 3e, 62%c
(eq 1)
D
2) D 2O
S4k
2e, 85%b
OH
D
D Br
N
O +
Br
N
2a, 81% Me
N
Me
N 3f, 76%c
(eq 2) D
4j', 20% yield
The promising functional group tolerance and mild reaction conditions of this protocol enable its application to the deuteration of pharmaceuticals and natural product derivatives (Scheme 3a). Introducing deuterium into menthol (7a) and glucofuranose (7b) derivatives were successfully realized in excellent yields. Deuterated naftifine (7c), pheniramine (7d), methylduloxetine (7e), diphenhydramine (7f), imipramine (7g), clomipramine (7h), aplysamine (7i) were achieved from the corresponding bromide precursors in 73 – 91% yield. A triazole derivative of estradiol (7j) was accommodated and deuterium was introduced in 82% yield. Additionally, deuterated estrone analogs (7k – 7m) were readily synthesized in 68 – 85% yield. In the case of estrone 7m, the carbonyl group adjacent to a quaternary carbon was compatible. Moreover, a formal isotopic exchange of the original C–H bond of
b
D
D
N
N 2f, 91% Me
O 1) tBuLi, THF, –78 $C
2) D 2O S4j
methyltocopherol (7n) was realized by performing both the bromination15a and deuteration in a one-pot fashion to eliminate the need for isolation of the bromo-precursors (Scheme 3b). Finally, we were delighted to find that the reaction was amenable to scale up using 20 equivalent of deuterium source without loss of efficiency (Scheme 3c).
N
D 2g, 91%
Me
N Me D 2h, 89%
N D
3h, 71%
N 3g, 82% D
N 3a, 91%c
a
Reactions were conducted on 0.5 mmol scale with 20 equiv of CD3CN. bWith N-Me-2-I-indole as substrate. cWith 50 equiv of CD3CN.
Precise deuteration of the specific bond of interest is necessary for methods to be useful in drug discovery and mechanistic studies. Such a highly selective deuteration is still a significant challenge for the HIE processes.11 In contrast, given the availability of diverse arylhalides,15 sitespecifically introducing deuterium into target molecules could be rapidly accessed by our methodology. To showcase this feature, pinpoint incorporation of deuterium into privileged heterocycles was carried out. Starting from
ACS Paragon Plus Environment
Journal of the American Chemical Society 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
bromo- or iodo-precursors, a library of deuterated indoles (2a, and 2e – 2h) were synthesized in moderate to good yield (81 – 91%) with excellent deuterium incorporation (Scheme 4a). Similarly, quinolones (3a, and 3c – 3h) were successfully labeled (from C2 to C8) in 31 – 91% yield (Scheme 4b). A number of synthetic methods with potassium alkoxides and organosilanes have been reported involving the intermediacy of either radicals or silyl anions.13,16 We first considered the possibility of a radical pathway. The addition of TEMPO, which is able to shut down the silyl radical addition,16e has little effect to the deuteration reaction (see Scheme S2a in SI). Moreover, when a radical probe substrate 1-bromo-2-(but-3-en-1-yl)benzene was used, ipsodebromination product was obtained in 54% yield exclusively without the observation of radical cyclization reaction (Scheme S2b).17 Those results indicate that a free radical species is less possible. Inspired by previous studies reporting silyl substitutions of aryl halides by Ito et al18 and Strohmann et al,19 a putative mechanism involving an anionic pathway is proposed to be active under our reation conditions (Scheme S2c). The mixture of KOMe and Me3SiSiMe3 may slowly generate trimethylsilyl anion or a nucleophilic hypervalentsilane species,16 which attacks the aryl bromide to form an aryl carbanion.18 The transient carbanion is instantaneously trapped by the large excess of CD3CN to provide the desired deuterated product. Detailed studies aimed at understanding mechanism will be carried out to further probe this hypothesis. In summary, a general KOMe/disilane-mediated ipsodehalogenative deuteration reaction in CD3CN was developed. This method features operationally simple procedures, mild reaction conditions, readily available reagents, and good functional group tolerance. A diverse range of valuable deuterated (hetero)arenes, natural products, and pharmaceuticals were isotopically labeled with excellent deuterium incorporation and specificity. Further mechanistic studies are currently ongoing. ASSOCIATED CONTENT The Supporting Information is available free of charge on the ACS Publications website. Experimental procedures, characterization data and NMR spectra for all new compounds (PDF)
AUTHOR INFORMATION Corresponding Author
[email protected]; Notes The authors declare no competing financial interest. A provisional patent has been filed.
ACKNOWLEDGMENT We gratefully acknowledge the NSFC (21602160, 21772148), the Fundamental Research Funds for the Central Universities
(2042018kf0017), the NSF under the CCI Center for Selective C−H Functionalization (CCHF), CHE-1700982, National Program for 1000 Young Talents of China, Wuhan University, and Caltech for financial support. Prof. Qiang-Hui Zhou and his group are appreciated for generously sharing their lab space. Profs. Martin Oestreich (T.U. Berlin), Nasri Nesnas (F.I.T.), and Yong Liang (Nanjing Univ.) are thanked for helpful discussions. We also thank Dr. Hongbing Liu (Wuhan Institute of Physics and Mathematics, CAS) for the measurements of 2H NMR spectra.
REFERENCES (1) (a) Miyashita, M.; Sasaki, M.; Hattori, I.; Sakai, M.; Tanino, K. Science 2 0 0 4 , 305, 495. (b) Quasdorf, K. W.; Huters, A. D.; Lodewyk, M. W.; Tantillo, D. J.; Garg, N. K.; J. Am. Chem. Soc. 2 0 1 2 , 134, 1396. (2) (a) Wiberg, K. B. Chem. Rev. 1 9 5 5 , 55, 713. (b) Simmons, E. M.; Hartwig, J. F. Angew. Chem. Int. Ed. 2 0 1 2 , 51, 3066. (3) Selected example, see: Bergner, G.; Albert, C. R.; Schiller, M.; Bringmann, G.; Schirmeister, T.; Dietzek, B.; Niebling, S.; Schlücker, S.; Popp, J. Analyst 2 0 1 1 , 136, 3686. (4) For a seminal report, see: (a) Belleau, B.; Burba, J.; Pindell, M.; Reiffenstein, J. Science 1 9 6 1 , 133, 102. For selected reviews, see: (a) Timmins, G. S. Expert Opin. Ther. Pat. 2 0 1 4 , 24, 1067. (b) Harbeson, S. L.; Tung, R. D. MedChem. News 2 0 1 4 , 8. (c) Mullard, A. Nat. Rev. Drug Discov. 2 0 1 6 , 15, 219. (d) Harbeson, S. L.; Tung, R. D. Annu. Rep. Med. Chem. 2 0 1 1 , 46, 403. (e) Gant, T. G. J. Med. Chem. 2 0 1 4 , 57, 3595. (5) (a) Helfenbein, J.; Lartigue, C.; Noirault, E.; Azim, E.; Legailliard, J.; Galmier, M. J.; Madelmont, J. C. J. Med. Chem. 2 0 0 2 , 45, 5806. (b) Shao, L.; Hewitt, M. C. Drug News Perspect. 2 0 1 0 , 23, 398. (c) Elmore, C. S.; Bragg, R. A. Bioorg. Med. Chem. Lett. 2 0 1 5 , 25, 167. (6) Selected examples: (a) Morgan, A. J.; Nguyen, S.; Uttamsingh, V.; Bridson, G.; Harbeson, S.; Tung, R.; Masse, C. E. J. Labeled Comp. Radiopharm. 2 0 1 1 , 54, 613. (b) Sharma, R.; Strelevitz, T. J.; Gao, H.; Clark, A. J.; Schildknegt, K.; Obach, R. S.; Ripp, S. L.; Spracklin, D. K.; Tremaine, L. M.; Vaz, A. D. N. Drug Metab. Dispos. 2 0 1 2 , 40, 625. (c) Stringer, R. A.; Williams, G.; Picard, F.; Sohal, B.; Kretz, O.; McKenna, J.; Krauser, J. A. Drug Metab. Dispos. 2 0 1 4 , 42, 954. (7) For reviews, see: (a) Atzrodt, J.; Derdau, V.; Fey, T.; Zimmerman, J. Angew. Chem. Int. Ed. 2 0 0 7 , 46, 7744. (b) Atzrodt, J.; Derdau,V.; Kerr, W. J.; Reid, M. Angew. Chem. Int. Ed. 2 0 1 8 , 57, 3022. (8) A particularly attractive method was established by Wood and coSpiegel, D. A.; workers using D2O as the deuterium source, see: (a) Wiberg, K. B.; Schacherer, L. N.; Medeiros, M. R.; Wood, J. L. J. Am. Chem. Soc. 2 0 0 5 , 127, 12513. For a recent example, see: (b) Soulard, V.; Villa, G.; Vollmar, D. P.; Renaud, P. J. Am. Chem. Soc. 2 0 1 8 , 140, 155. (9) (a) Bailey, W. F.; Patricia, J. J. J. Organomet. Chem. 1 9 8 8 , 352, 1. (b) Yus, M. Chem. Soc. Rev. 1 9 9 6 , 25, 155. (c) Yus, M. Synlett 2 0 0 1 , 8, 1197. (d) Reich, H. J. J. Org. Chem. 2 0 1 2 , 77, 5471. (10) For a review of metal-mediated reductive hydrodehalogenation: (a) Alonso, F.; Beletskaya, I. P; Yus, M. Chem. Rev. 2 0 0 2 , 102, 4009. For selected examples of transition-metal catalyzed dehalogenative deuteration: (b) Desmarets, C.; Kuhl, S.; Schneider, R.; Fort, Y. Organometallics 2 0 0 2 , 21, 1554. (c) Janni, M.; Peruncheralathan, S. Org. Biomol. Chem. 2 0 1 6 , 14, 3091. (d) Kuriyama, M.; Hamaguchi, N.; Yano, G.; Tsukuda, K.; Sato, K.; Onomura, O. J. Org. Chem. 2 0 1 6 , 81, 8934. (e) Donald, C. S.; Moss, T. A.; Noonan, G. M.; Roberts, B.; Durham, C. E. Tetrahedron Lett. 2 0 1 4 , 55, 3305. (f) Johansen, S. K.; Sørensen, L.; Martiny, L. J. Label Compd. Radiopharm. 2 0 0 5 , 48, 569. For selected examples of radical mediated dehalogenative deuteration: (g) Mutsumi, T.; Iwata, H.; Maruhashi, K.; Monguchi, Y.; Sajiki, H. Tetrahedron 2 0 1 1 , 67, 1158. (h) Miura, Y.; Oka, H.; Yamano, E.; Morita, M. J. Org. Chem. 1 9 9 7 , 62, 1188, and ref 8. For a recent example of hydrodehalogenation of haloarenes by NaH/LiI: (i) Ong, D. Y.; Tejo, C.; Xu, K.; Hirao, H.; Chiba, S. Angew. Chem. Int. Ed. 2 0 1 7 , 56, 1840. (11) Selected examples: (a) Klei, S. R.; Golden, J. T.; Tilley, T. D.; Bergman, R. G. J. Am. Chem. Soc. 2 0 0 2 , 124, 2092. (b) Esaki, H.; Ito, N.;
ACS Paragon Plus Environment
Page 4 of 5
Page 5 of 5 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Journal of the American Chemical Society Sakai, S.; Maegawa, T.; Monguchi, Y.; Sajiki, H. Tetrahedron 2 0 0 6 , 62, 10954. (c) Zhou, J.; Hartwig, J. F. Angew. Chem. Int. Ed. 2 0 0 8 , 47, 5783. (d) Ma, S.; Villa, G.; Thuy-Boun, P. S.; Homs, A.; Yu, J.-Q. Angew. Chem. Int. Ed. 2 0 1 4 , 53, 734. (e) Li, W.; Wang, M.-M.; Hu, Y.; Werner, T. Org. Lett. 2 0 1 7 , 19, 5768. (f) Yu, R. P.; Hesk, D.; Rivera, N.; Pelczer, I.; Chirik, P. J. Nature 2 0 1 6 , 529, 195. (g) Loh, Y. Y.; Nagao, K.; Hoover, A. J.; Hesk, D.; Rivera, N. R.; Colletti, S. L.; Davies, I. W.; MacMillan, D. W. C. Science 2 0 1 7 , 358, 1182. (h) Valero, M.; Weck, R.; Güssregen, S.; Atzrodt, J.; Derdau, V. Angew. Chem. Int. Ed. 2 0 1 8 , 57, 8159. (12) During the preparation of this manuscript, three different strategies for deuteration/tritiation were reported independently. (a) For a two-step procedure for the selective deuteration/tritiation of pyridines and diazines: Koniarczyk, J.; Hesk, D.; Overgard, A.; Davies, I. W.; McNally, A. J. Am. Chem. Soc. 2 0 1 8 , 140, 1990. (b) For a radical dehalogenative deuteration reaction with porous CDSe nano sheet as catalyst: Liu, C.; Chen, Z.; Su, C.; Zhao, X.; Gao, Q.; Ning, G.-H.; Zhu, H.; Tang, W.; Leng, K.; Fu, W.; Tian, B.; Peng, X.; Li, J.; Xu, Q.-H.; Zhou, W.; Loh, K. P. Nat. Commun. 2 0 1 8 , 9, 80. (c) For a palladium (II)-mediated tritiation: Yang, H.; Dormer, P. G.; Rivera, N. R.; Hoover, A. J. Angew. Chem. Int. Ed. 2 0 1 8 , 57, 1883. (13) For nucleophilic silylation of aryl halides: (a) Brook, A. G.; Wolfe, S. J. Am. Chem. Soc. 1 9 5 7 , 79, 1431. (b) Shippey, M. A.; Dervan, P. B. J. Org. Chem. 1 9 7 7 , 42, 2654. For direct C–H silylation: (c) Postigo, A.; Rossi, R. A. Org. Lett. 2 0 0 1 , 3, 1197. (d) Toutov, A. A.; Liu, W.-B.; Betz, K. N.; Fedorov, A.; Stoltz, B. M.; Grubbs, R. H. Nature, 2 0 1 5 , 518, 80. (14) (a) Firouzabadi, H.; Karimi, B. Syn. Commun. 1 9 9 3 , 23, 1633. (b) Hudrlik, P. F.; Arango, J. O.; Hijji, Y. M.; Okoro, C. O.; Hudrlik, A. M. Can. J. Chem. 2 0 0 0 , 78, 1421. (c) Weickgenannt, A.; Oestreich, M. Chem. Asian. J. 2 0 0 9 , 4, 406. Ar
KOMe Me 3SiSiMe3
Br
Ar
CD 3CN
D N
Me
N
Me
Imipramine
Site-specific deuteration Exclusive deuterium incorporation Mild reaction conditions Good functional group tolerance >60 examples
D
S
D
Me
(15) A large number of functional group rich and diverse arylhalides are commercially available or readily prepared. For selected regioselective halogenation methods: (a) Song, S.; Sun, X.; Li, X.; Yuan, Y.; Jiao, N. Org. Lett. 2 0 1 5 , 17, 2886. (b) Wengryniuk, S. E.; Weickgenannt, A.; Reiher, C.; Strotman, N. A.; Chen, K.; Eastgate, M. D.; Baran, P. S. Org. Lett. 2 0 1 3 , 15, 792. (c) Sun, K.; Lv, Y.; Wang, J.; Sun, J.; Liu, L.; Jia, M.; Liu, X.; Li, Z.; Wang, X. Org. Lett. 2 0 1 5 , 17, 4408. (d) Kumar, L.; Mahajan, T.; Sharma, V.; Agarwal, D. D. Ind. Eng. Chem. Res. 2 0 1 1 , 50, 705. For a recent review, see: (e) Petrone, D. A.; Ye, J.; Lautens, M. Chem. Rev. 2 0 1 6 , 116, 8003. (16) (a) Corriu, R. J. P.; Guérin, C.; Henner, B.; Wang, Q.-J. Organometallics, 1 9 9 1 , 10, 2297. (b) Lachance, N.; Gallant, M. Tetrahedron Lett. 1 9 9 8 , 39, 171. (d) Chuit, C.; Corriu, R. J. P.; Reye, C.; Young, J. C. Chem. Rev. 1 9 9 3 , 93, 1371. (e) Liu, W. -B.; et al., J. Am. Chem. Soc. 2 0 1 7 , 139, 6867. (f) Zhang, L.; Yang, H.; Jiao, L. J. Am. Chem. Soc. 2 0 1 6 , 138, 7151. (g) Smith, A. J.; Young, A.; Rohrbach, S.; O’Connor, E. F.; Allison, M.; Wang, H.-S.; Poole, D. L.; Tuttle, T.; Murphy, J. A. Angew. Chem. Int. Ed. 2 0 1 7 , 56, 13747. (17) (a) Newcomb, M.; Curran, D. P. Acc. Chem. Res. 1 9 8 8 , 21, 206. (b) Yasuda, H.; Uenoyama, Y.; Nobuta, O.; Kobayashi, S.; Ryu, I. Tetrahedron Lett. 2 0 0 8 , 49, 367. (18) (a) Yamamoto, E.; Izumi, K.; Horita, Y.; Ito, H. J. Am. Chem. Soc. 2 0 1 2 , 134, 19997. (b) Uematsu, R.; Yamamoto, E.; Maeda, S.; Ito, H.; Taketsugu, T. J. Am. Chem. Soc. 2 0 1 5 , 137, 4090. (19) (a) Das̈chlein, C.; Bauer, S. O.; Strohmann, C. Eur. J. Inorg. Chem. 2 0 1 1 , 1454. (b) Strohmann, C.; Bindl, M.; Fraaß, V. C.; Hörnig, J. Angew. Chem. Int. Ed. 2 0 0 4 , 43, 1011.
N Me
Me O
D D
O Methylduloxetine
MeO
Insert Table of Contents artwork here
ACS Paragon Plus Environment
H H
H
Methylestrone
